Form 4: Vistagen Therapeutics Director FitzPatrick Receives Stock Options
SEC Form 4 Filing
Margaret M. FitzPatrick, a director at Vistagen Therapeutics, was granted stock options for 12,500 shares on March 4, 2024.
Summary
- On March 4, 2024, Margaret M. FitzPatrick, a director of Vistagen Therapeutics, Inc., was granted stock options.
- The options are for 12,500 shares of common stock.
- The exercise price of the options is $4.85 per share.
- The options vest in twelve equal monthly installments, starting on the grant date.
- The options expire on March 4, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, indicating a neutral sentiment.
Positives
- The grant of stock options aligns the director's interests with those of the shareholders.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel.
Comparison to Industry Standards
- Stock option grants to directors are a standard practice across publicly traded companies, particularly in the biotech sector.
- The vesting schedule of twelve equal monthly installments is fairly typical.
- The exercise price is set at the market price on the grant date.
Key Dates
| Date | Description |
|---|---|
| 2023-09-07 | Date of Power of Attorney execution. |
| 2024-03-04 | Date of the stock option grant. |
| 2024-03-04 | Stock options vest in twelve equal monthly installments, beginning on this date. |
| 2024-03-06 | Date of Form 4 signature. |
| 2034-03-04 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.